Estimation of Supar and YKL-40 in generalized periodontitis and diabetes.

Not Applicable

Completed

• Conditions: Health Condition 1: E119- Type 2 diabetes mellitus without complications

• Registration Number: CTRI/2022/07/044107
• Lead Sponsor: Bhavana Vunnam

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2022-11-22
• Last Update Posted: 3 April 2023

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 80

Inclusion Criteria

1. Age group 35-75 years.

2. Patients who have not received any periodontal treatment in previous six months.

3. Patients diagnosed with T2DM as per American Diabetes Association criteria (2019).

4. Patients with a diagnosis of generalized periodontitis as per World Workshop Classification criteria (2017).

Exclusion Criteria

1.Smokers and alcoholics.

2.Patients with systemic diseases like hypertension, cardiovascular diseases, rheumatoid arthritis, tumours, autoimmune diseases and renal diseases.

3.Pregnant, lactating females and post menopausal women.

4.Any other systemic disease which can alter the course of periodontal disease.

5.Patients on medications like anti-inflammatory drugs, antibiotics and anti-epileptic drugs in the past 6 months.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
comparatively evaluate salivary and serum levels of suPAR and YKL-40 in generalized periodontitis and T2DM. <br/ ><br>Explore any correlation of suPAR with YKL-40 levels and clinical parametersTimepoint: Baseline

Secondary Outcome Measures

Name	Time	Method
ot ApplicableTimepoint: Not Applicable